Stefanie Kennon‐McGill

Researcher

University of Arkansas for Medical Sciences

faculty

12 h-index 31 pubs 805 cited

Research Areas

Drug-Induced Hepatotoxicity and Protection Metabolism and Genetic Disorders Cannabis and Cannabinoid Research Liver Disease Diagnosis and Treatment Health Disparities and Outcomes Maternal and Perinatal Health Interventions Pharmacological Effects and Toxicity Studies Diet and metabolism studies

Links

ORCID Research Group

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Stefanie Kennon‐McGill's research investigates the metabolic and molecular underpinnings of liver injury, particularly concerning acetaminophen toxicity. Her work has explored how specific metabolic pathways, such as hepatic pyruvate and alanine metabolism, contribute to antioxidant capacity and resistance to oxidative stress in the liver. Kennon‐McGill has also examined the role of lactate dehydrogenase as a prognostic marker in acetaminophen-induced acute liver failure, identifying altered signaling pathways associated with this condition. Her research extends to the safety of acetaminophen use in patients with compensated cirrhosis and the potential therapeutic effects of exogenous compounds like phosphatidic acid in mitigating liver injury, exploring mechanisms involving interleukin-6 signaling and inter-organ crosstalk.

Further research by Kennon‐McGill addresses the use and perceptions of cannabis and its derivatives, including cannabidiol, particularly in vulnerable populations such as pregnant individuals. She has utilized a human quad liver-on-chip system to bridge the gap between animal models and human responses in toxicology and pharmacology studies related to cannabis extracts. Kennon‐McGill's scholarship metrics include an h-index of 12, with 31 total publications and 805 citations. She has collaborated extensively with colleagues at the University of Arkansas for Medical Sciences, including Mitchell R. McGill (9 shared publications), Eric U. Yee (4 shared publications), Felicia D. Allard (3 shared publications), and Jeffery H. Moran (2 shared publications).

Metrics

h-index: 12
Publications: 31
Citations: 805

Selected Publications

NAPQI is absent in the mouse brain after sub-hepatotoxic and hepatotoxic doses of acetaminophen (2025) DOI
Human quad liver-on-chip system as a tool toward bridging the gap between animals and humans regarding toxicology and pharmacology of a cannabidiol-rich cannabis extract (2024) DOI
Hepatic pyruvate and alanine metabolism are critical and complementary for maintenance of antioxidant capacity and resistance to oxidative insult (2023) DOI
Factors associated with ever using cannabidiol in a cohort of younger pregnant people (2023) DOI
Proteomics Indicates Lactate Dehydrogenase Is Prognostic in Acetaminophen-Induced Acute Liver Failure Patients and Reveals Altered Signaling Pathways (2022) DOI
Proteomics Indicates Lactate Dehydrogenase is Prognostic in Acetaminophen-induced Acute Liver Failure Patients and Reveals a Role for LKB1-AMPK Signaling (2021) DOI
Short‐Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis (2021) DOI
Exogenous phosphatidic acid reduces acetaminophen-induced liver injury in mice by activating hepatic interleukin-6 signaling through inter-organ crosstalk (2021) DOI
Ototoxicity and Drug Transport in the Cochlea (2021) DOI
55715 Quantification of Neonatal THC Exposure Following Prenatal Marijuana Use (2021) DOI